The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Synthesis and Biological Evaluation of Dimeric RGD Peptide−Paclitaxel Conjugate as a Model for Integrin-Targeted Drug Delivery
Open accessAbstract
Targeting drugs to receptors involved in tumor angiogenesis is a novel and promising approach to improve cancer treatment. In this study, we evaluated the antitumor activity of paclitaxel (PTX) conjugated with a bicyclic peptide E[c(RGDyK)](2) (RGD) in a metastatic breast cancer cell line (MDA-MB-435). The cyclic RGD peptide selectively binds to alpha(v) integrin receptors that are highly expressed in metastatic cancer cells. PTX, an antimicrotubule agent, is a potent antitumor agent commonly used in the treatment of advanced metastatic breast cancer. The in vitro results showed that RGD peptide inhibited cell cycle proliferation by arresting cells in G(0)/G(1)-phase. The PTX-RGD conjugate inhibited cell proliferation with activity comparable to that observed for paclitaxel, both of which were mediated by an arrest of G(2)/M-phase of the cell cycle followed by apoptosis. Although the PTX-RGD conjugate showed slightly decreased integrin binding affinity than the unconjugated peptide, it indicated integrin specific accumulation in vivo. (125)I-Labeled PTX-RGD showed highest tumor uptake at 2 h postinjection (2.72 +/-0.16%ID/g) and best tumor/background contrast after 4 h postinjection. Our results demonstrate the potential of tumor-targeted delivery of paclitaxel based on the specific recognition of cell adhesion molecule alpha(v)beta(3) integrin to reduce toxicity and enhance selective killing of cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammen, M., Choi, S.-K., & Whitesides, G. M. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.0.co;2-3 · Cited by 4,110
Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., & Henson, P. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.7.2207 · Cited by 3,316
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Xiong, J.-P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., & Arnaout, M. A. (2002) · Science · doi:10.1126/science.1069040 · Cited by 1,613
Life, death, and the pursuit of apoptosis.
White, E. (1996) · Genes & Development · doi:10.1101/gad.10.1.1 · Cited by 1,311
Crystal Structure of the Extracellular Segment of Integrin αVβ3
Xiong, J.-P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S. L., & Arnaout, M. A. (2001) · Science · doi:10.1126/science.1064535 · Cited by 1,276
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
Brooks, P. C., Strömblad, S., Klemke, R., Visscher, D., Sarkar, F. H., & Cheresh, D. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118227 · Cited by 828
Resolution of Lung Inflammation by CD44
Teder, P., Vandivier, R. W., Jiang, D., Liang, J., Cohn, L., Puré, E., Henson, P. M., & Noble, P. W. (2002) · Science · doi:10.1126/science.1069659 · Cited by 677
A reevaluation of integrins as regulators of angiogenesis
Hynes, R. O. (2002) · Nature Medicine · doi:10.1038/nm0902-918 · Cited by 548
Oxygen Isotopes and the Moon-Forming Giant Impact
Wiechert, U., Halliday, A. N., Lee, D.-C., Snyder, G. A., Taylor, L. A., & Rumble, D. (2001) · Science · doi:10.1126/science.1063037 · Cited by 457
Chen, X., Park, R., Tohme, M., Shahinian, A. H., Bading, J. R., & Conti, P. S. (2004) · Bioconjugate Chemistry · doi:10.1021/bc0300403 · Cited by 260
Self-citationDeutsch, H. M., Glinski, J. A., Hernandez, M., Haugwitz, R. D., Narayanan, V. L., Suffness, M., & Zalkow, L. H. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00124a011 · Cited by 221
MicroPET imaging of breast cancer ?-integrin expression with Cu-labeled dimeric RGD peptides
CHEN, X., LIU, S., HOU, Y., TOHME, M., PARK, R., BADING, J., & CONTI, P. (2004) · Molecular Imaging & Biology · doi:10.1016/j.mibio.2004.06.004 · Cited by 212
Self-citationAngiogenesis modulation in cancer research: novel clinical approaches
Cristofanilli, M., Charnsangavej, C., & Hortobagyi, G. N. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd819 · Cited by 179
Gottschalk, K.-E., & Kessler, H. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20021018)41:20<3767::aid-anie3767>3.0.co;2-t · Cited by 171
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide
Chen, X. S., Park, R. J.-H., Hou, Y., Khankaldyyan, V., Gonzales-Gomez, I., Tohme, M. S., Bading, J. R., Laug, W. E., & Conti, P. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1452-2 · Cited by 158
Self-citationChemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Esteva, F. J., Valero, V., Pusztai, L., Michaud, L. B., Buzdar, A. U., & Hortobágyi, G. N. (2001) · The Oncologist · doi:10.1634/theoncologist.6-2-133 · Cited by 154
Cridland, M. D. (1981) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1981.tb135817.x · Cited by 154
Buerkle, M. A., Pahernik, S. A., Sutter, A., Jonczyk, A., Messmer, K., & Dellian, M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600141 · Cited by 130
A small molecule antagonist of the α v β3 integrin suppresses MDA-MB-435 skeletal metastasis
Harms, J. F., Welch, D. R., Samant, R. S., Shevde, L. A., Miele, M. E., Babu, G. R., Goldberg, S. F., Gilman, V. R., Sosnowski, D. M., Campo, D. A., et al. (2004) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000024763.69809.64 · Cited by 109
Safavy, A., Bonner, J. A., Waksal, H. W., Buchsbaum, D. J., Gillespie, G. Y., Khazaeli, M. B., Arani, R. B., Chen, D., Carpenter, M., & Raisch, K. P. (2003) · Bioconjugate Chemistry · doi:10.1021/bc020033z · Cited by 77
Molema, G. (2002) · Pharmaceutical Research · doi:10.1023/a:1020312220968 · Cited by 29
Sacco, M. G., Soldati, S., Catò, E. M., Cattaneo, L., Pratesi, G., Scanziani, E., & Vezzoni, P. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301817 · Cited by 20
Cited by
Drug Delivery with Carbon Nanotubes for In vivo Cancer Treatment
Liu, Z., Chen, K., Davis, C., Sherlock, S., Cao, Q., Chen, X., & Dai, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1468 · Cited by 1,348
Self-citationNanotechnology-based drug delivery systems
Suri, S. S., Fenniri, H., & Singh, B. (2007) · Journal of Occupational Medicine and Toxicology · doi:10.1186/1745-6673-2-16 · Cited by 755
Self-targeting fluorescent carbon dots for diagnosis of brain cancer cells.
Zheng, M., Ruan, S., Liu, S., Sun, T., Qu, D., Zhao, H., Xie, Z., Gao, H., Jing, X., & Sun, Z. (2015) · ACS Nano · doi:10.1021/acsnano.5b05575 · Cited by 593
Nanoparticles and targeted drug delivery in cancer therapy
Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M., & Jadidi-Niaragh, F. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.07.015 · Cited by 510
Temming, K., Schiffelers, R. M., Molema, G., & Kok, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.10.002 · Cited by 467
Metadata
- Authors
- Chen, X., Plasencia, C., Hou, Y., & Neamati, N.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-01-27
- Volume
- 48
- Issue
- 4
- Pages
- 1098-1106
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1982117697
- Cited by
- 256
- References
- 23
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.